LEMBOREXANT

Lemborexant is a dual orexin receptor antagonist promoting sleep onset and maintenance. Benefits include improved sleep continuity. Side effects include next‑day drowsiness, impaired driving ability, nightmares, and rare complex sleep behaviors.

Product Description


Mechanism of Action

LEMBOREXANT (ID 32275) demonstrates a high‑granularity biochemical interaction profile spanning catalytic‑domain modulation, multi‑layer signalling interference, mitochondrial‑network recalibration, redox‑state restructuring, ion‑flux redistribution, membrane‑electrochemical modulation, cytoskeletal‑architecture remodelling and transcription‑factor axis reprogramming. Its molecular topology supports interactions with catalytic residues, allosteric regulatory surfaces, transmembrane helices, hydrophobic receptor pockets, nucleotide‑binding cavities, redox-buffer modules and polymeric scaffolding proteins—enabling broad influence across metabolic, genomic, electrophysiological and structural regulatory networks.

Mechanistically, LEMBOREXANT may reshape phosphorylation‑flow geometry across ERK/MAPK/JNK/p38 cascades, modulate PI3K–AKT survival‑pathway architecture, alter G‑protein coupling logic, redistribute Ca²⁺ microdomains, shift IP₃/DAG signal amplitude, and recalibrate cAMP–PKA oscillatory behaviour. Mitochondrial effects include ETC‑complex rebalancing, ATP/ADP flux modulation, ROS‑threshold displacement, mitochondrial‑membrane potential polarity shifts and ER–mitochondria bidirectional stress‑signal integration.

Advanced Research Applications

  • Kinome‑scale catalytic‑cascade interference and pathway reconstruction
  • Ultra‑resolution receptor/ligand docking and conformational‑transition modelling
  • UPR/ER‑stress, mitophagy, autophagy and oxidative‑stress crosstalk research
  • Deep multi‑omics network reconstruction (RNA‑seq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal tension‑mapping, polymer turnover and mechano‑signalling analytics
  • Apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos modelling
  • Machine‑learning SAR/QSAR pipelines for predictive molecular optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation and antioxidant‑buffer system collapse
  • Mitochondrial fragmentation, membrane‑potential failure or ETC inhibition
  • Severe Na⁺/K⁺/Ca²⁺ ion‑homeostasis disruption
  • Cytoskeletal depolymerisation, actin/tubulin instability and loss of cellular mechanics
  • Membrane‑integrity failure and lipid‑bilayer thinning
  • NF‑κB, STAT and IRF inflammatory‑axis hyperactivation
  • Engagement of multi‑axis programmed‑cell‑death pathways
  • Epigenetic drift across methylation/acetylation domains

For expert laboratory research only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C22H20F2N4O2

Molecular Weight

410.4 g/mol

CAS Number

1369764-02-2

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Lemborexant; 1369764-02-2; Dayvigo; E-2006; E2006

IUPAC/Chemical Name

cis-(1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropane-1-carboxamide

InChl Key

MUGXRYIUWFITCP-PGRDOPGGSA-N

InChl Code

InChI=1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)/t18-,22+/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/56944144;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download